Photodynamic effect of protoporphyrin diarginate (PPArg2) on methicillin-resistant Staphylococcus aureus and human
Mariusz Grinholc1, Anna Kawiak, Julianna Kurlenda
1Department of Biotechnology, Division of Molecular Diagnostics, University of Gdansk and Medical University of Gdansk, Gdańsk, Poland. grinholc@biotech.ug.gda.pl
Abstract:
The worldwide rise in the antibiotic resistance of bacteria forces the development of alternative antimicrobial treatments. A potential approach is photodynamic inactivation (PDI). The aim of the present study was to determine the phototoxicity of protoporphyrin diarginate (PPArg(2)) against methicillin-resistant Staphylococcus aureus and human dermal fibroblasts. Different concentrations (0 to 20 microM) of PPArg(2) and light dose of 6 J cm(-2) were tested. Cell viability was evaluated using the methylthiazoletetrazolium (MTT) assay. Incubation with 10 microM followed by illumination yielded a 3.6 log(10)-unit reduction in the viable count for Staphylococcus aureus. At the same experimental conditions, only 22.5% of the fibroblasts were photoinactivated. Protoporphyrin diarginate at concentrations up to 20 microM demonstrated no toxicity towards S. aureus or fibroblasts when not irradiated. These results suggest that the protoporphyrin diarginate exerts a high bactericidal effect against methicillin-resistant S. aureus strain without harming eukaryotic cells.
Insights
Photodynamic inactivation (PDI) using protoporphyrin diarginate shows promise against antibiotic-resistant bacteria. This novel treatment effectively killed methicillin-resistant Staphylococcus aureus while sparing human skin cells.
Area of Science:
- Antimicrobial research
- Photodynamic therapy
- Bacteriology
Background:
- Rising antibiotic resistance necessitates novel antimicrobial strategies.
- Photodynamic inactivation (PDI) presents a potential alternative treatment.
- Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant public health threat.
Purpose of the Study:
- To evaluate the phototoxicity of protoporphyrin diarginate (PPArg(2)) against MRSA.
- To assess the safety of PPArg(2)-mediated PDI on human dermal fibroblasts.
Main Methods:
- Methylthiazole tetrazolium (MTT) assay was used for cell viability assessment.
- PPArg(2) concentrations ranging from 0 to 20 microM were tested.
- A light dose of 6 J cm(-2) was applied during experiments.
Main Results:
- PPArg(2) at 10 microM with light reduced MRSA viable count by 3.6 log(10) units.
- Under identical conditions, only 22.5% of human dermal fibroblasts were photoinactivated.
- PPArg(2) showed no inherent toxicity to either bacteria or fibroblasts without irradiation.
Conclusions:
- PPArg(2)-mediated PDI demonstrates significant bactericidal efficacy against MRSA.
- The treatment exhibits a favorable safety profile, with minimal impact on human dermal fibroblasts.
- PPArg(2) represents a promising therapeutic agent for combating antibiotic-resistant bacterial infections.
More Related Videos
05:12An In Vitro Model to Study the Effect of 5-Aminolevulinic Acid-mediated Photodynamic Therapy on Staphylococcus aureus Biofilm
Published on: April 16, 2018
08:56Investigation of a Blue Light LED Device to Suppress Wound Pathogens Using a Collagen-Based Synthetic Skin Model
Published on: February 24, 2026
Related Concept Videos
Staphylococcal Skin Infections
Mechanism of Antibiotic Resistance in MRSA
Clinical Significance of Antibiotic Resistance
